EUVIMEDEUVIMED entdecken
Fallbericht

Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty

Ian Marpuri, Mitchell E Geffner, Lily C Chao

Hormone Research in Paediatrics · 27.02.2025 · 99 (5) · 642-646

DOI: 10.1159/000544181 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 27.02.2025. Verfasst von Ian Marpuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Puberty, Precocious, Gonadotropin-Releasing Hormone, Drug Implants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Histrelin acetate implant (HI) is an approved treatment option for children with central precocious puberty. Implant duration has been reported to surpass the recommended replacement interval of 1–2 years. Implant breakage is a known potential adverse effect during the extraction procedure. However, the bioactivity of the retained fragment has not been reported previously. Case Presentation: We present 3 cases of females with central precocious puberty, who received HI for pubertal suppression and experienced implant breakage during extraction. In 2 cases, the retained fragment suppressed pubertal hormone for 5 years. In the third case, the HI was left in place due to loss of follow-up, and the patient was amenorrheic for the next 6 years. In all 3 cases, menstruation occurred after the HI fragments were surgically removed.

Conclusion

Our case series demonstrates that retained HI fragment can be bioactive for up to 5 years. If HI breakage occurs during removal, ultrasound localization and surgical extraction of the fragment should be performed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Puberty, PrecociousGonadotropin-Releasing HormoneDrug ImplantsHumansFemalePuberty SuppressionChildPuberty Inhibitors

Stichwörter der Autor:innen

AmenorrheaCentral precocious pubertyHistrelin implantPubertal suppression

Substanzen

histrelinGonadotropin-Releasing HormoneDrug ImplantsPuberty Inhibitors

Autor:innen und Institutionen

  • Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California, USA, lchao@chla.usc.edu.
  • Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, lchao@chla.usc.edu.

Zitieren

APA

Marpuri, I., Geffner, M. E., & Chao, L. C. (2025). Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty. Hormone Research in Paediatrics, 99(5), 642-646. https://doi.org/10.1159/000544181

Vancouver

Marpuri I, Geffner ME, Chao LC. Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty. Hormone Research in Paediatrics. 2025;99(5):642-646. doi:10.1159/000544181

BibTeX
@article{Marpuri2025,
  author = {Marpuri, Ian and Geffner, Mitchell E and Chao, Lily C},
  title = {Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty},
  journal = {Hormone Research in Paediatrics},
  year = {2025},
  volume = {99},
  number = {5},
  pages = {642--646},
  doi = {10.1159/000544181}
}
Kostenlos starten →